Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：0
|
作者：
Cardoso, Fatima [1 ]
Hirshfield, Kim M. [2 ]
Kraynyak, Kimberly A. [2 ]
Tryfonidis, Konstantinos [2 ]
Bardia, Aditya [3 ]
机构：
[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[2] Merck & Co Inc, Rahway, NJ USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;
D O I：
10.1038/s41523-024-00704-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.
引用
收藏
页数：15
相关论文
共 50 条
  • [41] Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive her2-negative breast cancer
    Gong, Chang
    Tan, Weige
    Chen, Kai
    You, Na
    Zhu, Shan
    Luo, Wei
    Xie, Xinhua
    Zeng, Yunjie
    Ouyang, Nengtai
    Li, Zhihua
    Zeng, Mushen
    Zhuang, ShiMei
    Lau, Wan-Yee
    Liu, Qiang
    Su, Fengxi
    Wang, Xueqin
    Song, Erwei
    CANCER RESEARCH, 2016, 76
  • [42] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [43] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [44] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study
    Tan, Ryan Ying Cong
    Ong, Whee Sze
    Lee, Kyung-Hun
    Park, Seri
    Iqbal, Jabed
    Park, Yeon Hee
    Lee, Jeong Eon
    Yu, Jong Han
    Lin, Ching-Hung
    Lu, Yen-Shen
    Ono, Makiko
    Ueno, Takayuki
    Naito, Yoichi
    Onishi, Tatsuya
    Lim, Geok-Hoon
    Tan, Su-Ming
    Lee, Han-Byoel
    Koh, Jiwon
    Han, Wonshik
    Im, Seock-Ah
    Tan, Veronique Kiak Mien
    Phyu, Nitar
    Wong, Fuh-Yong
    Tan, Puay Hoon
    Yap, Yoon-Sim
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (2D):
  • [46] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [47] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [48] Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer
    Gong, Chang
    Tan, Weige
    Chen, Kai
    You, Na
    Zhu, Shan
    Liang, Gehao
    Xie, Xinhua
    Li, Qian
    Zeng, Yunjie
    Ouyang, Nengtai
    Li, Zhihua
    Zeng, Musheng
    Zhuang, ShiMei
    Lau, Wan-Yee
    Liu, Qiang
    Yin, Dong
    Wang, Xueqin
    Su, Fengxi
    Song, Erwei
    EBIOMEDICINE, 2016, 11 : 199 - 209
  • [49] Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer
    Maleki, Elham
    Ghaedi, Kamran
    Shahanipoor, Kahin
    Kurdistani, Zana Karimi
    APMIS, 2018, 126 (04) : 303 - 308
  • [50] The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Grinshpun, Albert
    Sandusky, Zachary M.
    Jeselsohn, Rinath
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 169 - 181
12345